Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AtriCure Inc
ATRC
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$57.67
N/A
Últ. Act.: Oct 21, 4:00 PM
$57.67
N/A
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Ganancias:
Beneficios de Q3 2026 dentro de 12 días de ahora en mar nov 3rd, después del cierre del mercado
AtriCure Financials
AtriCure (ATRC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AtriCure Raises FY2026 GAAP EPS Guidance from $0.00-$0.04 to $0.05-$0.13 vs $0.05 Est
AtriCure (NASDAQ:ATRC) raises FY2026 GAAP EPS guidance from $0.00-$0.04 to $0.05-$0.13 vs $0.05 analyst estimate..
Benzinga Newsdesk
PRO
AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 1000 percent increase over losses of $(0.02) per share from the
Benzinga Newsdesk
PRO
AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M to $602.000M-$610.000M vs $604.990M Est
AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analyst estimate. Raises FY2026 sales outlook from $600.000 million-$610.000 million to $602.000 million-$610.000 million vs
Benzinga Newsdesk
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights
PRO
AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est
2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million to $82 million.
Benzinga Newsdesk
PRO
AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.06) by 100 percent. This is a 100 percent increase over losses of $(0.14) per share from the same
Benzinga Newsdesk
